Avaí Bio, Inc. develops cell-based therapies centered on genetically modified cell lines, protective encapsulation technologies and joint venture or licensing structures. The company, formerly Avant Technologies Inc., uses the AVAI ticker and has described a biotechnology focus spanning diabetes, age-related disorders and anti-aging applications.
Recurring developments include the Insulinova diabetes program, which pairs insulin-producing or regulating cells with encapsulation technology, and the Klothonova α-Klotho program, which uses encapsulated cells designed to produce the longevity protein α-Klotho. Company updates also cover GMP manufacturing steps such as master cell bank production, research presentations, partner collaborations and the completed corporate name change to Avaí Bio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.